Anti-3-[(18)F]FACBC positron emission tomography-computerized tomography and (111)In-capromab pendetide single photon emission computerized tomography-computerized tomography for recurrent prostate carcinoma: results of a prospective clinical trial.

Anti-3-[(18)F]FACBC positron emission tomography-computerized tomography and (111)In-capromab pendetide single photon emission computerized tomography-computerized tomography for recurrent prostate carcinoma: results of a prospective clinical trial.

Item

http://www.wikidata.org/entity/Q34139498

Q34139498

about

Anti-1-amino-3-18F-fluorocyclobutane-1-carboxylic acid: physiologic uptake patterns, incidental findings, and variants that may simulate disease.Recurrent prostate cancer detection with anti-3-[(18)F]FACBC PET/CT: comparison with CT.Reproducibility and reliability of anti-3-[¹⁸F]FACBC uptake measurements in background structures and malignant lesions on follow-up PET-CT in prostate carcinoma: an exploratory analysis 68Ga-PSMA-11 PET/CT for prostate cancer staging and risk stratification in Chinese patients.Novel Imaging of Prostate Cancer with MRI, MRI/US, and PET.Prostate Cancer Imaging with Novel PET Tracers.Imaging of local recurrence in prostate cancer.Localizing sites of disease in patients with rising serum prostate-specific antigen up to 1ng/ml following prostatectomy: How much information can conventional imaging provide?Diagnostic performance and safety of NMK36 (trans-1-amino-3-[18F]fluorocyclobutanecarboxylic acid)-PET/CT in primary prostate cancer: multicenter Phase IIb clinical trial.VPAC1 Targeted (64)Cu-TP3805 Positron Emission Tomography Imaging of Prostate Cancer: Preliminary Evaluation in Man.Change in Salvage Radiotherapy Management Based on Guidance With FACBC (Fluciclovine) PET/CT in Postprostatectomy Recurrent Prostate Cancer.Accumulation of trans-1-amino-3-[(18)F]fluorocyclobutanecarboxylic acid in prostate cancer due to androgen-induced expression of amino acid transporters.Antibody therapeutics for treating prostate cancer: where are we now and what comes next?PET Tracers Beyond FDG in Prostate Cancer.Spinal Metastatic Disease: A Review of the Role of the Multidisciplinary Team.Dynamic contrast-enhanced MRI for automatic detection of foci of residual or recurrent disease after prostatectomy.⁸⁹Zr-huJ591 immuno-PET imaging in patients with advanced metastatic prostate cancer.Diagnostic Performance and Safety of Positron Emission Tomography Using 18F-Fluciclovine in Patients with Clinically Suspected High- or Low-grade Gliomas: A Multicenter Phase IIb Trial.Fluorine-18 labeled amino acids for tumor PET/CT imaging Phase IIa Clinical Trial of Trans-1-Amino-3-(18)F-Fluoro-Cyclobutane Carboxylic Acid in Metastatic Prostate Cancer.Impact of 18F-Fluciclovine PET on Target Volume Definition for Postprostatectomy Salvage Radiotherapy: Initial Findings from a Randomized Trial.Multisite Experience of the Safety, Detection Rate and Diagnostic Performance of Fluciclovine (18F) Positron Emission Tomography/Computerized Tomography Imaging in the Staging of Biochemically Recurrent Prostate Cancer Molecular imaging and fusion targeted biopsy of the prostate.A PET/MRI study towards finding the optimal [18F]Fluciclovine PET protocol for detection and characterisation of primary prostate cancer.The use of PET/CT in prostate cancer.Economic evaluation of diagnostic localization following biochemical prostate cancer recurrence.Diagnostic Performance of 18F-Fluciclovine in Detection of Prostate Cancer Bone Metastases.Clinical trials involving positron emission tomography and prostate cancer: an analysis of the ClinicalTrials.gov database.Role of PET imaging for biochemical recurrence following primary treatment for prostate cancer Fluciclovine positron emission tomography in the setting of biochemical recurrence following local therapy of prostate cancer Clinical implications of PET/CT in prostate cancer management

P2860

Q34451031-1EC42168-C441-435D-9645-B46F4B3E2F2B Q34522627-645EB396-22AF-42CC-8FC6-F8029F5941B4 Q36839766-A6874BFD-DCCA-4A56-9183-65EB363CD381 Q37707083-1E5D9B33-AA38-40DF-BF07-61DDFDD658DA Q38606252-67ECB2EF-880E-4AE9-AFB0-D90EFF8FCC82 Q38732369-60D5D877-8A95-47A3-B5F0-2EB1E8745141 Q38852724-1793BA04-B999-4500-8A56-36C59DA58D15 Q38877792-2E7A1C3B-4CA3-485B-883B-D19B812C2A5F Q38924532-EA9082AE-47CC-47A6-89A3-7766C78FA834 Q38948710-7A02B1DA-79A8-45E9-997D-941F6A988789 Q38982759-940A84A4-4D6C-450E-8906-67F5420F5E66 Q38983205-1FD440AD-A719-4A36-BEEA-0258FCB554DE Q39000185-D245D154-A5DD-4958-A400-CEED1E95DF75 Q39003086-BDAC5CF2-46D1-4913-91E8-3AD1ABF8E365 Q39155149-F642145F-5ED7-4A20-9813-A000A424127C Q39268756-22F6B649-4E73-4C5D-8102-3E6CC5ED9D9B Q39828822-0C0ACB68-6723-43FD-B150-EB1B767B4C08 Q41026634-96360115-C29E-4CC0-845A-CA05A1B0A850 Q41694062-6181FB61-051D-4D0D-B074-389646F52EC8 Q41862609-70329C31-D2CB-4524-A94E-602A9CF58718 Q42319014-ED99EAF0-4AB3-4A05-9943-9B3B5B32825F Q42379563-566D68CE-4E98-49CD-9125-195144F37550 Q47608215-27879364-0D78-419A-BF37-A6A85FD8E517 Q48243611-D8416747-EF90-4FD3-BF67-86419707FA5D Q49919217-808B8A0D-7169-4FD9-B1F8-FC83AB56BC7F Q51035093-F368501D-D9EA-4095-868A-114BA7FA1A4A Q53682227-AC578D51-7E7F-4067-BB45-94750E5341CC Q55408329-E8319590-70A7-4244-9088-85427FCDA7A9 Q58562169-399C3D75-D8CA-4A28-BDC8-3752E1197284 Q59137129-D6ABDA11-5A36-40E4-BC91-C54A7D26FE79 Q59137133-16C7EB35-8922-4206-A57B-EA13D3BC4E4A

P2860

Anti-3-[(18)F]FACBC positron emission tomography-computerized tomography and (111)In-capromab pendetide single photon emission computerized tomography-computerized tomography for recurrent prostate carcinoma: results of a prospective clinical trial.

Item

http://www.wikidata.org/entity/Q34139498

description

2013 nî lūn-bûn

@nan

2013 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2013 թվականի հոտեմբերին հրատարակված գիտական հոդված

@hy

2013年の論文

@ja

2013年論文

@yue

2013年論文

@zh-hant

2013年論文

@zh-hk

2013年論文

@zh-mo

2013年論文

@zh-tw

2013年论文

@wuu

name

Anti-3-[

@nl

Anti-3-[(18)F]FACBC positron e ...... a prospective clinical trial.

@ast

Anti-3-[(18)F]FACBC positron e ...... a prospective clinical trial.

@en

type

Item

label

Anti-3-[

@nl

Anti-3-[(18)F]FACBC positron e ...... a prospective clinical trial.

@ast

Anti-3-[(18)F]FACBC positron e ...... a prospective clinical trial.

@en

prefLabel

Anti-3-[

@nl

Anti-3-[(18)F]FACBC positron e ...... a prospective clinical trial.

@ast

Anti-3-[(18)F]FACBC positron e ...... a prospective clinical trial.

@en

P1476

Anti-3-[(18)F]FACBC positron e ...... a prospective clinical trial.

@en

P2093

Adeboye O Osunkoya

http://www.w3.org/2001/XMLSchema#string

Ashesh B Jani

http://www.w3.org/2001/XMLSchema#string

Bital Savir-Baruch

http://www.w3.org/2001/XMLSchema#string

F Dubois Bowman

http://www.w3.org/2001/XMLSchema#string

Jonathon A Nye

http://www.w3.org/2001/XMLSchema#string

Mark M Goodman

http://www.w3.org/2001/XMLSchema#string

Oluwaseun A Odewole

http://www.w3.org/2001/XMLSchema#string

Peter T Nieh

http://www.w3.org/2001/XMLSchema#string

Pooneh Alaei-Taleghani

http://www.w3.org/2001/XMLSchema#string

Raghuveer K Halkar

http://www.w3.org/2001/XMLSchema#string

P2860

Cancer statistics, 2012

Impact of fusion of indium-111 capromab pendetide volume data sets with those from MRI or CT in patients with recurrent prostate cancer.

Natural history of progression after PSA elevation following radical prostatectomy.

Salvage radiotherapy for patients with PSA relapse following radical prostatectomy: issues and challenges.

RTOG GU Radiation oncology specialists reach consensus on pelvic lymph node volumes for high-risk prostate cancer

Detection of recurrent prostate carcinoma with anti-1-amino-3-18F-fluorocyclobutane-1-carboxylic acid PET/CT and 111In-capromab pendetide SPECT/CT

Update on fused capromab pendetide imaging of prostate cancer.

Imaging prostate cancer: an update on positron emission tomography and magnetic resonance imaging

Characterization of primary prostate carcinoma by anti-1-amino-2-[(18)F] -fluorocyclobutane-1-carboxylic acid (anti-3-[(18)F] FACBC) uptake

Biodistribution, tumor detection, and radiation dosimetry of 18F-DCFBC, a low-molecular-weight inhibitor of prostate-specific membrane antigen, in patients with metastatic prostate cancer.

P304

1446-1453

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/J.JURO.2013.10.065

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

191

http://www.w3.org/2001/XMLSchema#string

P50

David M Schuster

P577

2013-10-19T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

24144687

http://www.w3.org/2001/XMLSchema#string

P932

4155751

http://www.w3.org/2001/XMLSchema#string

Anti-3-[(18)F]FACBC positron emission tomography-computerized tomography and (111)In-capromab pendetide single photon emission computerized tomography-computerized tomography for recurrent prostate carcinoma: results of a prospective clinical trial.

about

P2860

P2860

Anti-3-[(18)F]FACBC positron emission tomography-computerized tomography and (111)In-capromab pendetide single photon emission computerized tomography-computerized tomography for recurrent prostate carcinoma: results of a prospective clinical trial.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P50

P577

P698

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P50

P577

P698

P932